Strong history of biomedical innovation and partnering​

2018
Aerie Pharmaceuticals and DSM expand collaboration agreement focused on novel drug delivery technology in ophthalmology
2017 Dyneema Purity® Black fiber
  Actamax FDA approval to begin pivotal clinical trial for Actamax™ Adhesion Barrier
2016 510(k) approval Porcine Pericardium Devices​
2015 Dyneema Purity® Radiopaque Cerclage Cable FDA 510(k) clearance
2014 In-house medical coating service plant US Dyneema Purity® fiber plant
  Dyneema Purity® 10 dtex fiber and Radiopaque fiber
  PRP Device FDA 510(k) clearance
  Cellular therapy development services
2013 Meso Bilayer Surgical Mesh FDA 510(k) clearance
  UHMWPE membrane technology
2012 Kensey Nash Acquisition
  Porcine Mesothelium Devices
2011 Actamax DSM-DuPont JV
  HQ move to US
  Settable Fiber Reinforced CPC BVFs​
  Porous Beta-TCP Preform BVFs
2010 Expanded portfolio for ophthalmic applications​
2009 Medivas technology acquisition for Drug Delivery
  Bionate® II PCU
  Next generation UH product
  VitroStealth® non-biofouling coatings
  Dental membrane
  Porcine Dermis Devices
2008 Acquisition of The Polymer Technology Group
  Cardiovascular drug delivery development partnership
  Dyneema Purity® fiber for cardiovascular and spinal applications
2007 Thrombectomy Catheters
2006 First sales Medical Coatings
  Start of UH and drug delivery activities
  BMM Public Private Partnership funded by Dutch government
  Surgical Tools
  Cartilage Repair​
2005 Biomedical EBA launched​
2004 Dyneema Purity® fiber for knee ligament fixation
  Oriented Self Reinforced Polymer Devices​
2003 Dyneema Purity® orthopedic sutures​
2002 Medical Coating R&D efforts started in DSM Desotech
2000 Degradable foamed polymer devices
  Collagen components​
  DSM Dyneema’s medical R&D efforts​

Our purpose is to create brighter lives for all

30K+

Over 30,000 ECM​
devices implanted

100K+​

Over 100,000 synthetic bone 
grafts manufactured per year​

30+​

Serving the Medical Device 
Industry for over 30 years​

Biomedical Brochure

DSM in biomedical: Advanced biomedical solutions to improve lives.

Read more

  • Our products

    DSM portfolio of innovative biomedical materials and process manufacturing technologies: Biomedical Polyethylenes, Biomedical polyurethanes, Collagen Technology, Device Development, and Extracellular Matrix (ECM) Technology. Learn more.

  • The markets we serve

    DSM Biomedical offers the broadest portfolio of biomedical materials and manufacturing across market applications, including orthopedics, ophthalmology, neurology, cardiology, diabetes, wound, and continence care.

This site uses cookies to store information on your computer.

Learn more